K. Nishimura et al. / Tetrahedron 62 (2006) 1512–1519
1517
3.3. Extraction and isolation
3.4.5. Tricalysiolide E (5). Amorphous powder; [a]D25
K203 (c 0.26, pyridine); UV (MeOH) lmax nm (log 3) 276
(3.99); IR (film) nmax 3389, 2925, 2852, 1746, 1669, 1605,
Cut and air-dried wood (1.44 kg) of T. dubia was extracted
with hot MeOH (3!6 L). After removal of MeOH under
reduced pressure, the residue (104 g) was placed on a
column of HP-20 (DIAION, 600 g) and eluted with H2O,
H2O–MeOH (1/1), H2O–MeOH (1/4), MeOH, and acetone
(each 3 L) sequentially to give five fractions. After removal
of the solvent, the residue of the H2O–MeOH (1/4) fraction
(17 g) was subjected to silica gel (Merck Kieselgel 60,
230–400 mesh, 200 g) column chromatography
eluting sequentially with EtOAc, CHCl3–MeOH (10/1),
CHCl3–MeOH (3/1), and MeOH (each 500 mL). After
evaporation the CHCl3–MeOH (10/1) fraction (1.2 g) was
subjected to aminopropyl-bonded silica gel (Chromatorex,
200–350 mesh, 40 g) column chromatography eluting
sequentially with CHCl3–MeOH (50/1, then 30/1, then 10/1),
and MeOH (each 100 mL) to give fractions 1–5. Fraction 2
(16.2 mg) was further applied to ODS HPLC eluting with
MeOH–H2O (43/57) to afford 4 (5.6 mg). Fraction 3
(465.0 mg) was further separated by ODS HPLC eluting
with MeOH–H2O (44/56) to afford 1 (141.5 mg), 3
(50.8 mg), and 5 (6.8 mg). The CHCl3–MeOH (3/1) fraction
(7.15 g) was subjected to aminopropyl-bonded silica gel
(35 g) column chromatography eluting sequentially with
CHCl3–MeOH (30/1, then 10/1, then 5/1, then 3/1), and
MeOH (each 100 mL) to give fractions A–G. Fraction B
(276.7 mg) was further purified by repeated ODS HPLC
using MeOH–H2O (40/60) and then MeCN–H2O (18/82) to
afford 6 (14.8 mg). Fraction E (551.7 mg) was further
purified by repeated ODS HPLC using MeOH–H2O (40/60)
and then MeCN–H2O (17/83) to afford 2 (7.7 mg).
1
1464, 1455, 1445, 1259, 1213, 1055, 1021 cmK1; H and
13C NMR data, Tables 1 and 2; HRESIMS m/z 331.1901
[MCH]C (calcd for C20H27O4, 331.1909).
3.4.6. Tricalysiolide
F (6). Amorphous powder;
[a]2D5 K218 (c 0.14, pyridine); UV (MeOH) lmax nm
(log 3) 270 (3.89); IR (film) nmax 3419, 2927, 2867, 1781,
1747, 1672, 1608, 1454, 1395, 1209, 1017 cmK1; H and
1
13C NMR data, Tables 1 and 2; HRESIMS m/z 347.1882
[MCH]C (calcd for C20H27O5, 347.1858).
3.5. Identification of structural relations between the
terpenoids by synthetic procedures (Scheme 1)
3.5.1. Preparation of compound 7. To a solution of 1
(20.0 mg, 0.060 mmol) in pyridine–CH2Cl2 (1/1, 1 mL)
were added p-bromobenzoyl chloride (66.0 mg,
0.301 mmol) and 4-(dimethylamino)pyridine (8.0 mg,
0.065 mmol) in one portion. After stirring at room
temperature for 4 h, the mixture was diluted with
EtOAc. The extract was washed successively with 5%
aqueous HCl and brine, dried (MgSO4), filtered, and
concentrated to give a residue, which was then purified
by silica gel column chromatography with CHCl3–MeOH
(50/1) to afford p-bromobenzoyl ester 7 (29.0 mg, 94%) as
colorless prisms (pyridine); mp 230–232 8C; [a]2D5 K92 (c
0.11, CHCl3); IR (film) nmax 3442, 2924, 2852, 1721, 1679,
1
1647, 1452, 1396, 1266, 1013 cmK1; H NMR (500 MHz,
pyridine-d5) d 8.07 (d, 2H, JZ8.4 Hz), 7.61 (d, 2H, JZ
8.4 Hz), 5.75 (s, 1H), 4.93 (d, 1H, JZ11.3 Hz), 4.76 (t, 1H,
JZ9.3 Hz), 4.71 (d, 1H, JZ11.3 Hz), 2.49 (br s, 1H), 2.12
(m, 1H), 2.06 (m, 1H), 1.97–1.92 (m, 2H), 1.89 (d, 1H, JZ
14.4 Hz), 1.84 (d, 1H, JZ14.4 Hz), 1.71–1.63 (m, 4H),
1.59–1.43 (m, 6H), 1.16 (d, 1H, JZ7.9 Hz), 0.98 (td, 1H,
JZ13.8, 3.3 Hz), 0.69 (s, 3H); 13C NMR (125 MHz,
pyridine-d5) d 174.9, 173.7, 166.2, 132.0 (2C), 131.7 (2C),
130.1, 128.1, 111.5, 81.4, 79.3, 70.1, 53.8, 53.4, 48.7, 46.4,
44.7, 42.9, 40.0, 37.9, 35.8, 29.9, 26.2, 22.0, 19.3, 14.7;
HRESIMS m/z 515.1410 [MCH]C (calcd for C27H32O5Br,
515.1433).
3.4. Characteristics of each terpenoid
3.4.1. Tricalysiolide A (1). Amorphous solid; [a]2D5 K215
(c 0.11, CHCl3); UV (MeOH) lmax nm (log 3) 217 (4.29),
276 (1.25); IR (film) nmax 3365, 2932, 2865, 1775, 1742,
1
1645, 1044, 1021 cmK1; H and 13C NMR data, Tables 1
and 2; HRESIMS m/z 333.2074 [MCH]C (calcd for
C20H29O4, 333.2066).
3.4.2. Tricalysiolide B (2). Amorphous powder; [a]D25
K160 (c 0.33, pyridine); UV (MeOH) lmax nm (log 3) 215
(3.93); IR (film) nmax 3394, 2929, 2866, 1754, 1735, 1657,
1
1451, 1220, 1038 cmK1; H and 13C NMR data, Tables 1
3.5.2. Reduction of compound 2. Sodium borohydride
(2.5 mg, 0.066 mmol) was added to a solution of 2 (5.0 mg,
0.014 mmol) in EtOH (1.5 mL), and then the mixture was
stirred at room temperature for 5 min. After evaporation of
the solvent, the residue was purified by ODS HPLC with
MeCN–H2O (23/77) to give a compound [1.7 mg, 36%,
[a]2D5 K186 (c 0.09, CHCl3)], which was shown to be
identified to the natural product 1, by comparison of their 1H
NMR and mass spectra, and optical rotations.
and 2; HRESIMS m/z 349.2033 [MCH]C (calcd for
C20H29O5, 349.2015).
3.4.3. Tricalysiolide C (3). Colorless prisms (CHCl3–
MeOH); mp 243–246 8C; [a]2D5 K243 (c 0.11, CHCl3); UV
(MeOH) lmax nm (log 3) 217 (4.46); IR (film) nmax 3419,
2933, 2865, 1762, 1656, 1452, 1194, 1170, 1053 cmK1; 1H
and 13C NMR data, Tables 1 and 2; HRESIMS m/z 363.2182
[MCH]C (calcd for C21H31O5, 363.2171).
3.5.3. Treatment of compound 3 with lithium hydroxide.
To a solution of 3 (5.0 mg, 0.014 mmol) in THF–H2O (10/1,
1.5 mL) was added lithium hydroxide monohydrate
(3.0 mg, 0.071 mmol), and the mixture was stirred at room
temperature for 48 h. After addition of acetic acid (1 mL) to
the mixture, it was evaporated to dryness. The residue was
subjected to ODS HPLC with MeCN–H2O (23/77) to give a
compound [4.2 mg, 87%, [a]2D5 K173 (c 0.11, pyridine)],
3.4.4. Tricalysiolide D (4). Colorless prisms (CHCl3–
MeOH); mp 251–253 8C; [a]2D5 K198 (c 0.25, pyridine);
UV (MeOH) lmax nm (log 3) 217 (4.13); IR (film) nmax
3398, 2937, 2864, 1750, 1646, 1448, 1159, 1069, 1047,
1014 cmK1 1H and 13C NMR data, Tables 1 and 2;
;
HRESIMS m/z 347.2232 [MCH]C (calcd for C21H31O4,
347.2222).